Literature DB >> 31817839

NGF-Enhanced Vasculogenic Properties of Epithelial Ovarian Cancer Cells Is Reduced by Inhibition of the COX-2/PGE2 Signaling Axis.

Maritza P Garrido1,2, Iván Hurtado1,2, Manuel Valenzuela-Valderrama3,4, Renato Salvatierra1, Andrea Hernández1, Margarita Vega1,2, Alberto Selman2, Andrew F G Quest4,5, Carmen Romero1,2,4.   

Abstract

Epithelial ovarian cancer (EOC) is a lethal gynecological neoplasia characterized by extensive angiogenesis and overexpression of nerve growth factor (NGF). Here, we investigated the mechanism by which NGF increases vascular endothelial growth factor (VEGF) expression and the vasculogenic potential of EOC cells, as well as the contribution of the cyclooxygenase 2/prostaglandin E2 (COX-2/PGE2) signaling axis to these events. EOC biopsies and ovarian cell lines were used to determine COX-2 and PGE2 levels, as well as those of the potentially pro-angiogenic proteins c-MYC (a member of the Myc transcription factors family), survivin, and β-catenin. We observed that COX-2 and survivin protein levels increased during EOC progression. In the EOC cell lines, NGF increased the COX-2 and PGE2 levels. In addition, NGF increased survivin, c-MYC, and VEGF protein levels, as well as the transcriptional activity of c-MYC and β-catenin/T-cell factor/lymphoid enhancer-binding factor (TCF-Lef) in a Tropomyosin receptor kinase A (TRKA)-dependent manner. Also, COX-2 inhibition prevented the NGF-induced increases in these proteins and reduced the angiogenic score of endothelial cells stimulated with conditioned media from EOC cells. In summary, we show here that the pro-angiogenic effect of NGF in EOC depends on the COX-2/PGE2 signaling axis. Thus, inhibition COX-2/PGE2 signaling will likely be beneficial in the treatment of EOC.

Entities:  

Keywords:  COX-2/PGE2; NGF; VEGF; beta-catenin; c-MYC; epithelial ovarian cancer; survivin; vasculogenesis

Year:  2019        PMID: 31817839     DOI: 10.3390/cancers11121970

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  7 in total

1.  Interplay between cyclooxygenase‑2 and microRNAs in cancer (Review).

Authors:  Zexiong Gong; Weiguo Huang; Baiyun Wang; Na Liang; Songkai Long; Wanjun Li; Qier Zhou
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

2.  NGF/TRKA Promotes ADAM17-Dependent Cleavage of P75 in Ovarian Cells: Elucidating a Pro-Tumoral Mechanism.

Authors:  Maritza P Garrido; Christopher Vallejos; Silvanna Girardi; Fernando Gabler; Alberto Selman; Fernanda López; Margarita Vega; Carmen Romero
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

3.  Bone Marrow Mesenchymal Stem Cells Overexpressing HIF-1α Prevented the Progression of Glucocorticoid-Induced Avascular Osteonecrosis of Femoral Heads in Mice.

Authors:  Xin-Xin Zhang; Xu Liang; Sen-Rui Li; Kuang-Jin Guo; Dai-Feng Li; Tian-Fang Li
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.064

4.  3,3'-Diindolylmethane modulates aryl hydrocarbon receptor of esophageal squamous cell carcinoma to reverse epithelial-mesenchymal transition through repressing RhoA/ROCK1-mediated COX2/PGE2 pathway.

Authors:  Peiyao Zhu; Huayun Yu; Kun Zhou; Yu Bai; Ruiqun Qi; Shuguang Zhang
Journal:  J Exp Clin Cancer Res       Date:  2020-06-16

5.  NGF/TRKA Decrease miR-145-5p Levels in Epithelial Ovarian Cancer Cells.

Authors:  Maritza P Garrido; Ignacio Torres; Alba Avila; Jonás Chnaiderman; Manuel Valenzuela-Valderrama; José Aramburo; Lorena Oróstica; Eduardo Durán-Jara; Lorena Lobos-Gonzalez; Carmen Romero
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

Review 6.  Role of Mitochondria in Interplay between NGF/TRKA, miR-145 and Possible Therapeutic Strategies for Epithelial Ovarian Cancer.

Authors:  Daniela B Vera; Allison N Fredes; Maritza P Garrido; Carmen Romero
Journal:  Life (Basel)       Date:  2021-12-21

Review 7.  Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.

Authors:  Maritza P Garrido; Allison N Fredes; Lorena Lobos-González; Manuel Valenzuela-Valderrama; Daniela B Vera; Carmen Romero
Journal:  Biomedicines       Date:  2021-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.